ASTELLAS PHARMA EUROPE LTD.
To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT02377609
- Locations
- 🇬🇧
Site: 6, London, United Kingdom
🇫🇷Site: 7, Clichy, France
🇫🇷Site: 3, Paris, France
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 863
- Registration Number
- NCT02320773
- Locations
- 🇸🇰
Site SK42103 CMFF, sro, Vranov Nad Topľou, Slovakia
🇸🇰Site SK42105 ProCare Ziar nad Hronom, Žiar Nad Hronom, Slovakia
🇬🇷Site GR30012 Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
- Conditions
- Interventions
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 688
- Registration Number
- NCT02288247
- Locations
- 🇩🇪
Site DE49017, Ulm, Germany
🇪🇸Site ES34003, Madrid, Spain
🇪🇸Site ES34005, Lugo, Spain
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT02254967
- Locations
- 🇭🇺
Site HU36010, Budapest, Hungary
🇬🇷Site GR30007, Athens, Greece
🇬🇷Site GR30004, Athens, Greece
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 850
- Registration Number
- NCT02118896
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇲🇽Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Mexico
🇨🇭Universitätsspital Zürich, Zurich, Switzerland
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 2300
- Registration Number
- NCT02057484
- Locations
- 🇵🇱
Site PL48005, Lodz, Poland
🇵🇱Site PL48004, Szczecin, Poland
🇧🇪Site BE32002, Brussels, Belgium
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT01933022
- Locations
- 🇳🇱
Site NL31005 St. Antonius ziekenhuis, Nieuwegein, Netherlands
🇳🇱Site NL31004 Radboudumc, Nijmegen, Netherlands
🇳🇱Site NL31001 Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
- Conditions
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 2174
- Registration Number
- NCT01908829
- Locations
- 🇺🇸
Urology Center of Central Florida, Kissimmee, Florida, United States
🇺🇸Alliance Urology Specialists, Greensboro, North Carolina, United States
🇳🇴Site: 47005, Bekkestua, Norway
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
- Conditions
- Interventions
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01775397
- Locations
- 🇪🇸
H.U. Gregorio Maranon, Madrid, Spain
🇩🇪Universitätsklinikum, Essen, Germany
🇩🇪Charité, Berlin, Germany
Observation of the Use of QUTENZA™ in Standard Clinical Practice
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 429
- Registration Number
- NCT01737294
- Locations
- 🇦🇹
Site 101 Krankenhaus der Barmherzigen Brüder Abteilung für Anästhesiologie, Intensivmedizin und Schmerztherapie Johannes von Gott Platz 1, Vienna, Austria
🇬🇷Site 206 Dimosthenis Mitsikostas Hellenic Navy Hospital of Athens - Neurology Clinic, Athens, Attica, Greece
🇦🇹Site 106 Interdisziplinäre Schmerzambulanz Univ. Klinik f. Anästhesiologie und Intensivmedizin Graz Auenbruggerplatz 29, Linz, Austria